Fidelity Investments
ATNM icon

Fidelity Investments’s Actinium Pharmaceuticals ATNM Stock Holding History

Fidelity Investments’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79 Sell
79
-14,294
-99% -$17K ﹤0.01% 5277
2025
Q4 		$19.5K Sell
14,373
-6,727
-32% -$9.81K ﹤0.01% 4471
2025
Q3 		$33.8K Sell
21,100
-3,217
-13% -$5.24K ﹤0.01% 4150
2025
Q2 		$34K Buy
24,317
+11,738
+93% +$17.6K ﹤0.01% 4076
2025
Q1 		$20.3K Buy
12,579
+7,839
+165% +$9.95K ﹤0.01% 4220
2024
Q4 		$5.97K Sell
4,740
-3,771
-44% -$5.85K ﹤0.01% 4625
2024
Q3 		$16K Buy
8,511
+2,610
+44% +$10.3K ﹤0.01% 4273
2024
Q2 		$43.7K Buy
5,901
+2,999
+103% +$24.7K ﹤0.01% 3685
2024
Q1 		$22.7K Sell
2,902
-26
-0.9% -$167 ﹤0.01% 3965
2023
Q4 		$14.9K Sell
2,928
-212
-7% -$1.09K ﹤0.01% 4088
2023
Q3 		$18.6K Buy
3,140
+2,860
+1,021% +$19K ﹤0.01% 3849
2023
Q2 		$2.08K Buy
280
+266
+1,900% +$2.26K ﹤0.01% 4584
2023
Q1 		$128 Buy
+14
New +$148 ﹤0.01% 4881
2020
Q3 		– Sell
-6
Closed – – 3660
2020
Q2 		$0 Hold
6
– – ﹤0.01% 3567
2020
Q1 		$0 Hold
6
– – ﹤0.01% 3606
2019
Q4 		$0 Buy
+6
New +$41 ﹤0.01% 3765

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's ATNM Position: Q1 2026 in Review

Fidelity Investments reduced its Actinium Pharmaceuticals (ATNM) stake by 99% in Q1 2026, selling an estimated $17K and leaving 79 shares worth $79. The position accounts for ﹤0.01% of the portfolio, ranked #5277.

Fidelity Investments first reported a position in ATNM in Q4 2019 and has held it in 16 quarters since. The position peaked at $43.7K in Q2 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Fidelity Investments held 79 shares of Actinium Pharmaceuticals worth $79 as of Q1 2026.
  • Fidelity Investments sold 14,294 Actinium Pharmaceuticals shares in Q1 2026, an estimated $17K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5277 holding.
  • Fidelity Investments first reported a position in Actinium Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
  • Fidelity Investments's Actinium Pharmaceuticals position peaked at $43.7K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.